Re-evaluation Note REV2012-06

Re-evaluation Update Clofentezine

(publié aussi en français)

26 September 2012

This document is published by the Health Canada Pest Management Regulatory Agency. For further information, please contact:

Publications
Pest Management Regulatory Agency
Health Canada
2720 Riverside Drive
A.L. 6604-E2
Ottawa, Ontario K1A 0K9

Internet: pmra.publications@hc-sc.gc.ca
healthcanada.gc.ca/pmra
Facsimile: 613-736-3758
Information Service:
1-800-267-6315 or 613-736-3799
pmra.infoserv@hc-sc.gc.ca

Canada

ISSN: 1925-0630 (print)
1925-0649 (online)

Catalogue number: H113-5/2012-6E (print version)
H113-5/2012-6E-PDF (PDF version)

© Her Majesty the Queen in Right of Canada, represented by the Minister of Health Canada, 2012

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of the Minister of Public Works and Government Services Canada, Ottawa, Ontario K1A 0S5.

In Canada, clofentezine is under re-evaluation by Health Canada's Pest Management Regulatory Agency (PMRA). The PMRA's pesticide re-evaluation program considers potential risks as well as the value of pesticide products to ensure they continue to meet standards of modern science and current policy established to protect human health and the environment. This Re-evaluation Note is an update on the re-evaluation status of clofentezine.

Clofentezine is an acaricide, registered in Canada since 1989, used to control specific mite species in the egg stage and early larval stages. The end-use product is registered to control European red mite, two-spotted spider mite and McDaniel spider mite on apple and pear, European red mite and two-spotted spider mite on peaches and nectarines and two-spotted spider mite on raspberries, strawberries and outdoor deciduous nursery stock (Use-Site Categories 13, 14 and 27). The product is formulated as a liquid to be applied by ground equipment by farmers and farm workers.

The United States Environmental Protection Agency (USEPA) is also re-evaluating clofentezine as part of its registration review program and has published a final registration review work plan.[1] The PMRA will be working cooperatively with the USEPA on the re-evaluation of clofentezine and the overall Canadian re-evaluation timelines will be closely aligned with those of the USEPA.

The project plan discussed below outlines the anticipated areas of focus and risk assessments required to complete the re-evaluation of clofentezine. Should additional information become available during the re-evaluation period that affects the regulatory status of clofentezine, the PMRA will reconsider the area(s) of focus and risk assessments required.

Re-evaluation Project Plan

Human Health Assessment

- The toxicological database and endpoints for risk assessment have been reviewed recently and do not require further assessment. Therefore, this component of the re-evaluation is considered to be complete.

- The PMRA is currently conducting new assessments relating to occupational (mixer/loader/applicator and post application) and dietary exposure and will continue to work cooperatively with the USEPA.

Environmental Risk Assessment

- The PMRA is currently conducting new assessments and will continue to work cooperatively with the USEPA. These assessments will include calculations for buffer zones.

---

[1] United States Environmental Protection Agency, Clofentezine Final Work Plan for Registration Review, August 2007 (Docket ID: EPA-HQ-OPP-2006-0240).

- Additional data are required to complete the assessment and a data call-in was issued under the authority of section 19 of the *Pest Control Product Act* in 2009. As of June 2011, data were submitted and are currently under review.

Chemistry

- A reassessment of the chemistry database of technical grade clofentezine has been completed.

Anticipated Timeline for Re-evaluation

- A proposed re-evaluation decision for clofentezine is anticipated to be published for consultation in 2013.

Additional Information

If there are any questions or for additional information regarding the project plan, please contact Publications (please see contact information indicated on the cover page of the document).

PMRA documents can be found on our website at healthcanada.gc.ca/pmra or through the Pest Management Information Service.